Frank S Hodi
ECOG-ACRIN Cancer Research Group · Dana-Farber - Harvard Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Frank S Hodi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:34 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT02339571 · A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaNational Cancer Institute (NCI) · active not recruiting · Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 · principal investigator
- Ph1NCT02298959 · Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerNational Cancer Institute (NCI) · active not recruiting · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph2NCT01950390 · Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma · principal investigator
- Ph2NCT01134614 · Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · active not recruiting · Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Bioprinted 3D vascular cancer modelR01CA296990 · NCI · HARVARD UNIVERSITY · fiscal years 2026 · $604,102 awarded in 2026Same name and institution; not confirmed by an ID
- Cancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · fiscal years 2017 to 2026 · $1,934,873 awarded in 2026Same name and institution; not confirmed by an ID
- Program 35: MelanomaP30CA006516 · NCI · DANA-FARBER CANCER INST · fiscal years 2017 to 2026 · $48,198 awarded in 2026Same name and institution; not confirmed by an ID
- 3D Models of ImmunotherapyU01CA214369 · NCI · HARVARD UNIVERSITY · fiscal years 2017 to 2021 · $509,042 awarded in 2021Same name and institution; not confirmed by an ID
- Biomaterials to Create T Cell ImmunityU54CA244726 · NCI · HARVARD UNIVERSITY · fiscal years 2019 · $8,192,428 awarded in 2019Same name and institution; not confirmed by an ID
- Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV MelanomaR21CA143832 · NCI · DANA-FARBER CANCER INST · fiscal years 2010 to 2011 · $323,248 awarded in 2011Same name and institution; not confirmed by an ID
- CTLA-4 Blockade in GM-CSF Vaccinated PatientsR21CA105776 · NCI · DANA-FARBER CANCER INST · fiscal years 2003 to 2004 · $364,678 awarded in 2004Same name and institution; not confirmed by an ID
- MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATIONK08CA078880 · NCI · DANA-FARBER CANCER INST · fiscal years 1998 to 2002 · $87,426 awarded in 2002Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT02339571, NCT01950390
- Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 1994 to 2013Named on NCT02298959
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026Named on NCT02298959
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2014 to 2026Named on NCT02298959
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT01950390, NCT01134614
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:34 UTC. The ranking covers the 200 most relevant of 120 PubMed records, and a shared surname and initials can bring in a namesake. All 120 on PubMed
- Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med · 201012,255 citationsRCR 301.1
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med · 201210,484 citationsRCR 282.6
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med · 20156,463 citationsRCR 203.2
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature · 20144,405 citationsRCR 122.7
- 3,015 citationsRCR 114.3
- 2,979 citationsRCR 97.1
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.N Engl J Med · 20132,803 citationsRCR 76.7
- Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.Clin Cancer Res · 20092,575 citationsRCR 56.9
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med · 20152,291 citationsRCR 67.7
- 2,199 citationsRCR 66.5